Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Current and future treatment of amyloid neuropathies

Current and future treatment of amyloid neuropathies Amyloid neuropathies of acquired or genetic origin are disabling and life-threatening, until recently there were few treatment options available. Poor prognosis is related to progressive neuropathy and associated, although often underdiagnosed, cardiac involvement in specific transthyretin (TTR) gene mutations. Recent progress has modified prognosis and management of amyloid neuropathies. In TTR-familial amyloidosis with polyneuropathy, major changes have occurred over the last 30 years: better knowledge concerning genetics, phenotypes and epidemiology, and the advent of possible treatments. Liver transplantation, first performed in 1990, stopped disease progression, thus doubling survival in early onset V30M patients. More recently tetramer stabilizers (Tafamidis and Diflunisal) showed a significant reduction of progression of neuropathic scores; Tafamidis is now recommended in Stage I patients. Two multicentric clinical trials are now ongoing to evaluate TTR gene silencing by antisense Oligonucleotides (ASO) or siRNA. In the near future we should have new therapeutical options for patients with amyloid neuropathy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Expert Review of Neurotherapeutics Taylor & Francis

Current and future treatment of amyloid neuropathies

Download PDF
15 pages

Loading next page...
 
/lp/taylor-francis/current-and-future-treatment-of-amyloid-neuropathies-xw1VoHXPta

References (87)

Publisher
Taylor & Francis
Copyright
© Informa UK, Ltd
ISSN
1744-8360
eISSN
1473-7175
DOI
10.1586/14737175.2014.983905
pmid
25416603
Publisher site
See Article on Publisher Site

Abstract

Amyloid neuropathies of acquired or genetic origin are disabling and life-threatening, until recently there were few treatment options available. Poor prognosis is related to progressive neuropathy and associated, although often underdiagnosed, cardiac involvement in specific transthyretin (TTR) gene mutations. Recent progress has modified prognosis and management of amyloid neuropathies. In TTR-familial amyloidosis with polyneuropathy, major changes have occurred over the last 30 years: better knowledge concerning genetics, phenotypes and epidemiology, and the advent of possible treatments. Liver transplantation, first performed in 1990, stopped disease progression, thus doubling survival in early onset V30M patients. More recently tetramer stabilizers (Tafamidis and Diflunisal) showed a significant reduction of progression of neuropathic scores; Tafamidis is now recommended in Stage I patients. Two multicentric clinical trials are now ongoing to evaluate TTR gene silencing by antisense Oligonucleotides (ASO) or siRNA. In the near future we should have new therapeutical options for patients with amyloid neuropathy.

Journal

Expert Review of Neurotherapeutics – Taylor & Francis

Published: Dec 1, 2014

Keywords: antisense oligonucleotides; diflunisal; familial amyloid polyneuropathy; liver transplantation; patisiran; tafamidis; therapeutic patient education program; transthyretin; TTR gene silencing; TTR tetramer stabilizer

There are no references for this article.